Clinical trial

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

NCT05753566

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Rezvilutamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Androgen deprivation therapy (ADT) Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention SRT Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-03-01

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Biochemical Recurrenceunresolved

Interventions

RezvilutamideDRUG

Androgen deprivation therapy (ADT)DRUG

SRTRADIATION

Sponsors & collaborators

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical Schoollead sponsor

Jiangsu HengRui Medicine Co., Ltd.collaborator

Mapped research locations

NanjingJiangsu, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05753566 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.